ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aficamten

Also written as “Aficamten”, “BAY3723113” and “Aficamten (5 - 20 mg)”.

Its studies are mostly in Cardiomyopathy, Hypertrophic, led by 3 companies.

Drug pageAficamten: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 9, 202111 company-led studies, 4 open or runningNext primary completion: Mar 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cytokineticsits history only83 open or runningphase 3since Apr 9, 2021Dec 3, 2018Mar 2029phase 3 · NCT04848506
Corxel Pharmaceuticals20 open or runningphase 3since Oct 25, 2023Mar 3, 2021none ahead
Bayerits history only11 open or runningphase 3since Jun 10, 2025Jun 10, 2025none ahead

Also a collaborator on its studies: Sanofi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Corxel Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named aficamtenINNProposed as its International Nonproprietary Name in WHO's List 124 · before, BAY3723113
  2. Mar 3, 2021First study: phase 1 study in Cardiomyopathy, HypertrophicFirst studyNCT04783766 · 28 enrolled · China
  3. Oct 25, 2023Phase 3 study in Cardiomyopathy, HypertrophicNCT06116968 · 40 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Corxel Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06116968Cardiomyopathy, Hypertrophic · China3CompletedOct 20, 202540
NCT04783766Cardiomyopathy, Hypertrophic · China1CompletedAug 5, 202128

How it is read

Names in the registry

  • “Aficamten”, 4 entries
  • “BAY3723113”, 1 entry
  • “Aficamten (5 - 20 mg)”, 1 entry
  • “Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)”, 1 entry
  • “Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.